Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

This Innovative VE-822 Strategy Performs While You Go To Bed!

Implications for clinical practice are discussed. Copyright ? 2011 John Wiley & Sons, Ltd. ""To document prospective weight and anthropometric changes in children and adolescents during the first 12 weeks of treatment with risperidone and evaluate metabolic outcomes including plasma leptin levels. Eight patients with psychotic disorders (ages 11�C17) who had started risperidone (mean: 1.80?mg/day; sd?=?1.04) in the prior 4 weeks participated in this observational study. Fasting morning blood samples were obtained at baseline and week 8 to assess glucose, leptin, cortisol, insulin, and triglycerides. Measures of body mass index (BMI), weight, waist and hip circumference, blood PD0332991 supplier pressure, and heart rate were obtained weekly. Participants increased TSA HDAC in mean weight (4.16?kg; sd?=?4.36; p?=?0.03) and BMI (1.47?kg/m2; sd?=?1.53; p?=?0.03) with five out of eight gaining at least 7% of baseline body weight. They had a 4.03?cm (sd?=?3.82; p?=?0.02) increase in waist circumference and a 5.17?cm (sd?=?3.68; p?=?0.01) increase in hip circumference. Leptin trended higher, but did not reach statistical significance. There were no significant changes in glucose, insulin, cortisol, blood pressure, or heart rate. Subjects experienced significant increases in weight, BMI, hip and waist circumference during the first 3 months of treatment. Better powered research with more advanced anthropometric assessment is warranted to further elucidate mechanisms of antipsychotic associated weight gain in youth. Copyright ? 2010 John Wiley & Sons, Ltd. ""The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses VE822 in major depressive disorder. A prospective multi-site study of 106 patients (Caucasian and Han Chinese ethnicities) with major depressive disorder treated with either ESC or VEN was conducted. The 17-item Hamilton Depression scale (HDRS), Clinical Global Impression Scale, and an adverse events scale (UKU) were assessed over 8?weeks, blind to genotype. At the 8-week end point, a significant HDRS reduction for both ESC and VEN occurred (p?<?0.0001). The 5-HTTLPR l/l genotype was associated with significantly greater score reductions on the HDRS compared with s/s carriers (p?=?0.016) among Caucasian subjects receiving ESC (n?=?47). Response rates were significantly higher for l/l (92%) compared with l/s (61%) and s/s (46%) variants (p?=?0.042). For every l allele a participant carried, there was a 3.33 (95% confidence interval 1.25, 8.84; p?=?0.02) times greater odds of ESC response. No significant associations between any of the genotypes and adverse effects were found. Ethnicity may have differential effects on the 5-HTTLPR genotype-efficacy relationship.</div>
Sign In or Register to comment.